Myths vs facts: CYP2C19 and Langlebigkeit

The claim that CYP2C19 variants directly determine longevity is a myth. CYP2C19 is a cytochrome P450 enzyme primarily involved in drug metabolism (e.g., clopidogrel, proton pump inhibitors). Some studies have explored associations between CYP2C19 polymorphisms and age-related diseases, but effect sizes are small and inconsistent. Evidence is mostly from GWAS or mechanistic hypotheses, not from robust interventional trials. Fact: CYP2C19 has no proven direct role in human longevity. Its variants may influence drug response, which could indirectly affect health outcomes, but this is not a longevity gene. Consumer DNA tests that market CYP2C19 as a 'longevity gene' overstate the evidence. The clinical utility is limited to pharmacogenetics. For longevity, factors like telomere length, inflammation markers, and lifestyle are far more impactful. A balanced diet, exercise, and stress management remain the cornerstones of healthy aging.